Safety profile of the yellow fever vaccine Stamaril®: a 17-year review

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Expert Review of Vaccines

• Publication date

  2013-09-25

• Fields of study

  Medicine

• Identifiers
  DOI 10.1586/14760584.2013.836320PMID 24066727
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Notice to Readers

  2015cited by this paper
• Adverse events following yellow fever preventive vaccination campaigns in eight African countries from 2007 to 2010.

  2013cited by this paper
• Memory immune response and safety of a booster dose of Japanese encephalitis chimeric virus vaccine (JE-CV) in JE-CV-primed children

  2013cited by this paper
• Yellow fever vaccine. Recommendation of the U. S. Public Health Service Advisory Committee on Immunization Practices.

  2013cited by this paper
• Review of the risks and benefits of yellow fever vaccination including some new analyses

  2012cited by this paper
• Viscerotropic disease: case definition and guidelines for collection, analysis, and presentation of immunization safety data.

  2012cited by this paper
• From research to phase III: preclinical, industrial and clinical development of the Sanofi Pasteur tetravalent dengue vaccine.

  2011cited by this paper
• The revised global yellow fever risk map and recommendations for vaccination, 2010: consensus of the Informal WHO Working Group on Geographic Risk for Yellow Fever.

  2011cited by this paper
• Live-attenuated Tetravalent Dengue Vaccine in Dengue-naïve Children, Adolescents, and Adults in Mexico City: Randomized Controlled Phase 1 Trial of Safety and Immunogenicity

  2011cited by this paper
• Yellow Fever Virus Vaccine–associated Deaths in Young Women1

  2011cited by this paper
• Active and passive surveillance of yellow fever vaccine 17D or 17DD-associated serious adverse events: systematic review.

  2011cited by this paper
• Yellow fever vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP).

  2010cited by this paper
• Concomitant or sequential administration of live attenuated Japanese encephalitis chimeric virus vaccine and yellow fever 17D vaccine

  2010cited by this paper
• Preclinical and clinical development of YFV 17D-based chimeric vaccines against dengue, West Nile and Japanese encephalitis viruses.

  2010cited by this paper
• Yellow Fever Vaccine Post-marketing Surveillance in Brazil

  2010cited by this paper
• Short report: Incidence of yellow fever vaccine-associated neurotropic disease.

  2009cited by this paper
• TLR expression and NK cell activation after human yellow fever vaccination.

  2009cited by this paper
• Learning immunology from the yellow fever vaccine: innate immunity to systems vaccinology

  2009cited by this paper
• The Yellow Fever Virus Vaccine Induces a Broad and Polyfunctional Human Memory CD8+ T Cell Response1

  2009cited by this paper
• Immunogenicity and safety of yellow fever vaccination for 102 HIV-infected patients.

  2009cited by this paper
• Safety of 17D derived yellow fever vaccines.

  2009cited by this paper
• Clinical and Immunological Insights on Severe, Adverse Neurotropic and Viscerotropic Disease following 17D Yellow Fever Vaccination

  2009cited by this paper
• Immune response during adverse events after 17D-derived yellow fever vaccination in Europe.

  2008cited by this paper
• Case of yellow fever vaccine--associated viscerotropic disease with prolonged viremia, robust adaptive immune responses, and polymorphisms in CCR5 and RANTES genes.

  2008cited by this paper
• Yellow fever vaccine induces integrated multilineage and polyfunctional immune responses

  2008cited by this paper
• Yellow fever-associated viscerotropic disease in Barcelona, Spain.

  2008cited by this paper
• Evaluation of two yellow fever vaccines for routine immunization programs in Argentina

  2008cited by this paper
• Adverse event reports following yellow fever vaccination.

  2008cited by this paper
• Neurologic disease associated with 17D-204 yellow fever vaccination: a report of 15 cases.

  2007cited by this paper
• Early exposure to yellow fever vaccine during pregnancy

  2007cited by this paper
• High stability of yellow fever 17D-204 vaccine: a 12-year restrospective analysis of large-scale production.

  2007cited by this paper
• Acute viscerotropic disease following vaccination against yellow fever.

  2007cited by this paper
• Anaphylaxis: case definition and guidelines for data collection, analysis, and presentation of immunization safety data.

  2007cited by this paper
• Neurological adverse events temporally associated to mass vaccination against yellow fever in Juiz de Fora, Brazil, 1999-2005.

  2007cited by this paper
• The effects of yellow fever immunization (17DD) inadvertently used in early pregnancy during a mass campaign in Brazil.

  2006cited by this paper
• Vaccination coverage survey versus administrative data in the assessment of mass yellow fever immunization in internally displaced persons--Liberia, 2004.

  2006cited by this paper
• Yellow fever vaccine-associated viscerotropic disease and death in Spain.

  2006cited by this paper
• Yellow fever vaccine: an updated assessment of advanced age as a risk factor for serious adverse events.

  2005cited by this paper
• Immunogenicity and safety of BERNA-YF compared with two other 17D yellow fever vaccines in a phase 3 clinical trial.

  2005cited by this paper
• History of thymoma and yellow fever vaccination.

  2004cited by this paper
• Safety of the yellow fever vaccine during the September 2001 mass vaccination campaign in Abidjan, Ivory Coast.

  2004cited by this paper
• The changing epidemiology of yellow fever and dengue, 1900 to 2003: full circle?

  2004cited by this paper
• Viscerotropic and neurotropic disease following vaccination with the 17D yellow fever vaccine, ARILVAX.

  2004cited by this paper
• Postvaccinal inflammatory neuropathy: peripheral nerve biopsy in 3 cases

  2002cited by this paper
• Fatal myeloencephalitis following yellow fever vaccination in a case with HIV infection.

  2002cited by this paper
• Adverse events associated with 17D-derived yellow fever vaccination--United States, 2001-2002.

  2002cited by this paper
• Paternal age and maternal age are risk factors for miscarriage; results of a multicentre European study.

  2002cited by this paper
• Hepatitis and death following vaccination with 17D-204 yellow fever vaccine.

  2001cited by this paper
• Effects of yellow fever vaccination.

  2001cited by this paper
• Fever and multisystem organ failure associated with 17D-204 yellow fever vaccination: a report of four cases.

  2001cited by this paper
• Effects of yellow fever vaccination.

  2001cited by this paper
• Rarity of adverse effects after 17D yellow-fever vaccination.

  2001cited by this paper
• Effects of yellow fever vaccination.

  2001cited by this paper
• Maternal age and fetal loss: population based register linkage study

  2000cited by this paper
• Comparison of the immunogenicity and safety of two 17D yellow fever vaccines.

  1999cited by this paper
• Exposure to yellow fever vaccine in early pregnancy.

  1999cited by this paper
• Safety and immunogenicity of a new inactivated hepatitis A vaccine in concurrent administration with a typhoid fever vaccine or a typhoid fever + yellow fever vaccine.

  1997cited by this paper
• Yellow fever vaccines.

  1997cited by this paper
• Combined vaccination against yellow fever and typhoid fever: a comparative trial.

  1994cited by this paper
• Congenital yellow fever virus infection after immunization in pregnancy.

  1993cited by this paper
• Yellow fever vaccination and pregnancy: a four-year prospective study.

  1993cited by this paper
• Comparison of neurovirulence of different strains of yellow fever virus in mice.

  1986cited by this paper
• BEHAVIOR OF 17D YELLOW FEVER VIRUS IN RHESUS MONKEYS RELATION TO SUBSTRAIN, DOSE, AND NEURAL OR EXTRANEURAL INOCULATION

  1943cited by this paper

• Mathematical Model Analysis for Dynamics and Control of Yellow Fever and Malaria Disease Co-Infections

  2026cites this paper
• Yellow fever - An old foe with new developments.

  2024cites this paper
• Yellow Fever: Global Impact, Epidemiology, Pathogenesis, and Integrated Prevention Approaches.

  2024cites this paper
• Cynomolgus macaques as a translational model of human immune responses to yellow fever 17D vaccination

  2024cites this paper
• Enhanced safety surveillance of STAMARIL® yellow fever vaccine provided under the expanded access investigational new drug program in the USA

  2023cites this paper
• YF17D-vectored Ebola vaccine candidate protects mice against lethal surrogate Ebola and yellow fever virus challenge

  2023cites this paper
• Yellow fever vaccine-associated neurologic and viscerotropic disease: a 10-year case series of the French National Reference Center for arboviruses with clinical and immunological insights.

  2023cites this paper
• Incidence of Anaphylaxis to YF-VAX® Yellow Fever Vaccination: A Retrospective Evaluation of Vaccine Adverse Event Reports 1999-2018.

  2023cites this paper
• Arboviral vaccines for use in pregnant travelers.

  2023cites this paper
• A Systematic Review and a Meta-Analysis of the Yellow Fever Vaccine in the Elderly Population

  2022cites this paper
• Analysis of yellow fever prevention strategy from the perspective of mathematical model and cost-effectiveness analysis.

  2022cites this paper
• Neurovirulence, viscerotropism and immunogenicity of live attenuated yellow fever 17D vaccine virus in non-human primates.

  2022cites this paper
• Safety and immunogenicity following co-administration of Yellow fever vaccine with Tick-borne encephalitis or Japanese encephalitis vaccines: Results from an open label, non-randomized clinical trial

  2022cites this paper
• National review of reported Yellow fever vaccine incidents in the UK.

  2022cites this paper
• Genomic diversity contributes to the neuroinvasiveness of the Yellow fever French neurotropic vaccine

  2021cites this paper
• Next generation live-attenuated yellow fever vaccine candidate: Safety and immuno-efficacy in small animal models

  2021cites this paper
• Genomic diversity contributes to the neuroinvasiveness of the Yellow fever French neurotropic vaccine

  2021cites this paper
• A Yellow Fever 17D Virus Replicon-Based Vaccine Platform for Emerging Coronaviruses

  2021cites this paper
• A novel therapeutic HBV vaccine candidate induces strong polyfunctional cytotoxic T cell responses in mice

  2021cites this paper
• Vertebrate Responses against Arthropod Salivary Proteins and Their Therapeutic Potential

  2021cites this paper
• Immunization Strategies to Span the Spectrum of Immunocompromised Adults.

  2020cites this paper
• Severe Multiorgan Failure Following Yellow Fever Vaccination

  2020cites this paper
• Avaliação do teste de ELISA in house para Febre Amarela usando o domínio de helicase da proteína NS3 recombinante

  2020cites this paper
• Recommended/Required Travel Vaccines

  2019cites this paper
• Immunisation

  2019cites this paper
• Limited evolution of the yellow fever virus 17d in a mouse infection model

  2019cites this paper
• Brazilian recommendations on the safety and effectiveness of the yellow fever vaccination in patients with chronic immune-mediated inflammatory diseases

  2019cites this paper
• Innovative in cellulo method as an alternative to in vivo neurovirulence test for the characterization and quality control of human live Yellow Fever virus vaccines: A pilot study.

  2018cites this paper
• Yellow fever in the diagnostics laboratory

  2018cites this paper
• Immunoengineering through cancer vaccines – A personalized and multi‐step vaccine approach towards precise cancer immunity

  2018cites this paper
• 63 – Yellow Fever Vaccines

  2018cites this paper
• Was ist gesichert bei Reiseimpfungen?

  2018cites this paper
• Chapter 28 FUTURE PROSPECTS OF VACCINES AND ANTIBODIES IN BIODEFENSE

  2018cites this paper
• Yellow fever vaccine-associated neurotropic disease (YEL-AND) - A case report.

  2017cites this paper
• Safety of yellow fever vaccine in Indian travellers: A prospective observational study

  2016cites this paper
• Adverse event reports following yellow fever vaccination, 2007-13.

  2016cites this paper
• Safety Overview of a Recombinant Live-Attenuated Tetravalent Dengue Vaccine: Pooled Analysis of Data from 18 Clinical Trials

  2016cites this paper
• Yellow fever vaccine: worthy friend or stealthy foe?

  2016cites this paper
• First case of yellow fever vaccine-associated viscerotropic disease (YEL-AVD) in Hong Kong.

  2016cites this paper
• Adverse events following immunization: real causality and myths

  2016cites this paper
• Questions regarding the safety and duration of immunity following live yellow fever vaccination

  2016influential citation
• Operation United Assistance: infectious disease threats to deployed military personnel.

  2015cites this paper
• Evaluating the safety and immunogenicity of yellow fever vaccines: a systematic review

  2015influential citation
• Dengue and other flavivirus infections.

  2015cites this paper
• A systematic review of adverse events following immunization during pregnancy and the newborn period

  2015cites this paper
• Polyionic vaccine adjuvants: another look at aluminum salts and polyelectrolytes

  2015cites this paper
• Live virus vaccines based on a yellow fever vaccine backbone: standardized template with key considerations for a risk/benefit assessment.

  2015cites this paper
• Mathematical modeling provides kinetic details of the human immune response to vaccination

  2015cites this paper
• Chapter 32 – Vaccines

  2014cites this paper
• ive virus vaccines based on a yellow fever vaccine backbone : tandardized template with key considerations for a risk / benefit

  2014cites this paper
• Gelbfieberimpfung bei medikamentöser Immunsuppression – Aktuelle Empfehlungen für die reisemedizinische Beratung

  2014cites this paper
• Suspected YF-AND after yellow fever vaccination in Finland.

  2014cites this paper
• Risk groups for yellow fever vaccine-associated viscerotropic disease (YEL-AVD).

  2014cites this paper
• Plasmid DNA initiates replication of yellow fever vaccine in vitro and elicits virus-specific immune response in mice.

  2014cites this paper